Details

Autor(en) / Beteiligte

• Martin, Jarad M.
• Supiot, Stephane
• Berthold, Dominik R.

Titel

Pharmacotherapeutic Management of Locally Advanced Prostate Cancer: Current Status

Ist Teil von

• Drugs (New York, N.Y.), 2011-05, Vol.71 (8), p.1019-1041

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2011

Quelle

SpringerLink

Beschreibungen/Notizen

• Locally advanced prostate cancer (LAPC) is a heterogeneous entity usually embracing T3-4 and/or pelvic lymph-node-positive disease in the absence of established metastases. Outcomes for LAPC with single therapies have traditionally been poor, leading to the investigation of adjuvant therapies. Prostate cancer is a hormonally sensitive tumour, which usually responds to pharmacological manipulation of the androgen receptor or its testosterone-related ligands. As such, androgen deprivation therapy (ADT) has become an important adjuvant strategy for the treatment of LAPC, particularly for patients managed primarily with radiotherapy. Such results have generally not been replicated in surgical patients. With increased use of ADT has come improved awareness of the numerous toxicities associated with long-term use of these agents, as well as the development of strategies for minimizing ADT exposure and actively managing adverse effects. Several trials are exploring agents to enhance radiation cell sensitivity as well as the application of adjuvant docetaxel, an agent with proven efficacy in the metastatic, castrate-resistant setting. The recent work showing activity of cabazitaxel, sipuleucel-T and abiraterone for castrate-resistant disease in the post-docetaxel setting will see these agents investigated in conjunction with definitive surgery and radiotherapy.